Dec 10, 2020 10:03 PM (GMT+8) · EqualOcean
Today, Gilead Science( GILD.US )Announced the acquisition of MYR GmbH, a German clinical biotechnology company, for 1.15 billion euros in cash. In addition, if the future Myr GmbH hepatitis drug hepcludex is approved by FDA, Gilead will pay an additional milestone payment of up to 300 million euros.